Lakefront Biotherapeutics (GLPGF) EBITDA Margin Growth (3y) (2017 - 2026)
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) EBITDA Margin Growth (3y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.51 Bn | 197.52 Bn | 7.24 Bn | -347.00 |
| 2 | Gilead Sciences | 181.48 Bn | 178.30 Bn | 6.22 Bn | -15,844.00 |
| 3 | Vertex Pharmaceuticals | 132.45 Bn | 124.60 Bn | 2.84 Bn | -377.00 |
| 4 | Regeneron Pharmaceuticals | 82.87 Bn | 74.88 Bn | 3.93 Bn | -204.00 |
| 5 | Argenx Se | 61.59 Bn | 56.41 Bn | 1.37 Bn | 7,045.00 |
| 6 | Moderna | 54.72 Bn | 49.59 Bn | 52.00 Mn | -1,934.00 |
| 7 | Alnylam Pharmaceuticals | 34.13 Bn | 30.82 Bn | 992.69 Mn | 9,003.00 |
| 8 | Biogen | 31.29 Bn | 30.01 Bn | 1.96 Bn | -2,825.00 |
| 9 | Roivant Sciences | 30.31 Bn | 30.31 Bn | 1.16 Mn | -2.41 Mn |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn | -33,642.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -33,642.00 |
| Mar 31, 2026 | -95,868.00 |
| Dec 31, 2025 | 8,642.00 |
| Sep 30, 2025 | -31,893.00 |
| Jun 30, 2025 | -3,178.00 |
| Mar 31, 2025 | -19,617.00 |
| Dec 31, 2024 | 19,508.00 |
| Sep 30, 2024 | -6,381.00 |
| Jun 30, 2024 | -37,021.00 |
| Mar 31, 2024 | -847.00 |
| Dec 31, 2023 | 7,364.00 |
| Sep 30, 2023 | 2,886.00 |
| Jun 30, 2023 | 6,605.00 |
| Mar 31, 2023 | 2,036.00 |
| Dec 31, 2022 | 37.00 |
| Sep 30, 2022 | -7,981.00 |
| Jun 30, 2022 | 2,007.00 |
| Mar 31, 2022 | 14,560.00 |
| Dec 31, 2021 | -1,164.00 |
| Sep 30, 2021 | -6,820.00 |